Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (790)	7/11/2008 5:06:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Besides David Nance, Max Talbott and Robert Sobol, other clinicians not directly connected with INGN, participated in the CC including: Dr. Jack Roth, inventor of ADVEXIN and professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery, Section Chief, Thoracic Molecular Oncology, and Director, W.M. Keck Cancer Center for Innovative Cancer Therapies, M.D. Anderson Cancer Center, Houston, TX. Dr. John Nemunaitis, a principal investigator of Introgen’s phase III study and medical director, Mary Crowley Cancer Research Center at Baylor-Charles A. Sammons Cancer Center, Dallas, TX. Dr. John Hamm, Medical Director, Louisville Oncology at Norton Healthcare, Louisville, KY. and Dr. Jarrard Goodwin, Director, Sylvester Comprehensive Cancer Center/University of Miami Hospital and Clinics and Sylvester Professor, Department of Otolaryngology-Head and Neck Surgery. All of the participants expressed favorable opinions on Advexin; Dr. Hamm mentioned one patient he treated wich showed remarkably positive tumor response and was alive one year after treatment. Of course, I am aware of the existing bias against gene therapy , and the long campaign against INGN by the shorts. At last count, although the short position has come down some, still was about 16x the AvgDaylVol or 12% of the float.The insiders reportedly hold 25% and funds 35% of the shares. finance.yahoo.com Dr John N Kapoor, the Chairman of Akorn,and Preident of EJ Financial Enterprises,reportedly was holding more than 3M shrs at the end of May. finance.yahoo.com The approval of Advexin is no doubt still a long shot, but if it gets approved for Head & Neck tumors, it will probably be used in other tumors with abnormal p53, like in prostate and breast. In a series of prostate Cas, the expression of p53 was noted in 114 of 175 (65.1%) patients with a 5-year failure rate of 51.1%, compared with a 5-year failure rate of only 22% in p53 negative patients. At any rate, the FDA will not consider INGN's application for Advexin until next Yr., so it is still too early to draw final conclusions. I still don't mind keeping my position in INGN, since as previously mentioned,I figured that it has a negative cost.<g> The consensus of the 1Yr. "target" for INGN, according to Yahoo is around $8.75. I would be more than satisfied if it can get back to $5 <g> finance.yahoo.com Bernard